1. Lectures on symposia
2011
Jan 2011 High Content Screening on micronuclei and phospholipidosis. 6 th meeting
on: Human predictive toxicity and ADME/TOX studies, 27-28 Januari, 2011,
Mondial Research Group, Brussel, Belgium.
July 2011 Toxicogenomics in the pharmaceutical industry. 6th annual conference of SMi on ADMET
6-7 July, 2011, Crown’s Plaza St. James, London, United Kingdom.
2010
Jan 2010 High throughput screening analysis for genotoxicity and clastogenicity.
Feb 2010 Toxicogenomics in the pharmaceutical industry. Ecotec, 22th and 23th Februari,
Malaga, Spain.
Feb 2010 Toxicogenomics in the pharmaceutical industry. University of Maastricht,
Maastricht, Toxicogenomic Course, 26 February, 2008
Mar 2010 Analysing in vitro toxicity by high throughput and high content screening. High
content analysis. 4th Annual Meeting. 17th and 18th March, Berlin, Germany.
Jun 2010 ADME/TOX meeting, 7th and 8th June, Cologne, Germany.
Jul 2010 Segragation of genotoxic compounds. 5th annual conference of SMi on ADMET
7-8 July, 2010, Crown’s Plaza St. James, London, United Kingdom.
Aug 2010 SBS Course on High Content screening applications. High content screening for
micronuclei testing and phospholipidosis. 31th August, Coventry, UK
Sept 2010 Toxicogenomics in the pharmaceutical industry. EEMS, 16 th and 17th September,
Oslo, Norway.
Oct 2010 High throughput screening within the pharmaceutical industry. Luciferase based
genotoxicity assays. 14th and 15th October, BDS, Science Park, Amsterdam
2009
Jan 2009 High throughput screening analysis for genotoxicity and clastogenicity. 4rd meeting on:
Human predictive toxicity and ADME/TOX studies, 22-23 Januari, 2009, Mondial
Research Group, Brussel, Belgium.
Feb 2009 Identification of Non-Genotoxic Carcinogens with the Arylhydrocarbon receptor
(AhR) and the peroxisomal proliferator activating Receptor α (PPARα). Molecular
Conceptor, Case Studies in ADME/TOX predictions. D2.1.1
http://www.drugdesign.com
Jul 2009 High throughput screening for genotoxicity and clastogenicity. 4th annual conference
of SMi on ADMET 1-2 July, 2009, Crown’s Plaza St. James, London, United Kingdom.
Sep 2009 High throughput screening for genotoxicity and clastogenicity. Society for Medicines
Research (SMR), 24th September, National Heart and Lung Institute, Kensington,
London.
2008
Jan 2008 High throughput screening for in vitro toxicity testing: A gradual acceptance of
new test methods. 3rd meeting on: Human predictive toxicity and ADME/TOX
studies, 24-25 Januari, 2008, Mondial Research Group, Brussel, Belgium.
Feb 2008 Toxicogenomics in the pharmaceutical industry. University of Maastricht, Maastricht,
Toxicogenomic Course, 29 February, 2008.
Apr 2008 High throughput screening for in vitro toxicity testing. Workshop in vitro toxicity. 2-4
April, 2008, Milano, Italy.
July 2008 High throughput screening for in vitro toxicity testing: A gradual acceptance of new
test methods. 3rd annual conference of SMi on ADMET 2-3 July, 2008 The Hatton,
London, United Kingdom.
Sept 2008 High throughput screening for in vitro toxicity testing: Fast genotoxic screening.
Ehrlich II, 3-5 Oct, 2008, Gymnasium, Nürnberg, Germany.
Oct 2008 High throughput screening for in vitro toxicity testing: gradual acceptance. Miptec
meeting, satellite seminar of Promega, 14-16 Oct, 2008, Congress centre, Basel,
Switserland.
Nov 2008 High throughput screening analysis for genotoxicity and clastogenicity. Cell-Based
assays, SMi group, 19-20 Nov 2008, Crown Plaza – St. James, London, United
Kingdom.

2. 2007
Jan 2007 High throughput screening for in vitro toxicity testing. Predictive ADME/TOX meeting
Mondial Research Group, Brussel, Belgium.
Feb 2007 Promega Seminar, High throughput screening for in vitro toxicity testing. Utrecht, The
Netherlands.
Mar 2007 Validation methods of cellular assays for screening. Hogeschool Breda, Breda, The
Netherlands.
Jun 2007 Exploration of toxicity outcome measures. High content analysis, Vienna, Austria.
Sep 2007 High throughput screening for in vitro toxicity testing. SCTT congress, Salzau,
Germany.
Nov 2007 High throughput screening for in vitro toxicity testing. Rikilt, Wageningen, The
Netherlands.
2006
Mar 2006 Toxicogenomics course. University of Maastricht, Maastricht, The Netherlands.
Sep 2006 High throughput screening for in vitro toxicity testing. Morris, Leuven, Belgium.
2005
April 2005 Predictive ADME/Tox congress, High throughput screening for in vitro toxicity testing.
London, United Kingdom.
Sept 2005 Promega Seminar, High throughput screening for in vitro toxicity testing. Utrecht, The
Netherlands.
Nov 2005 High throughput screening for in vitro toxicity testing. Genotoxocity symposium, Oss,
The Netherlands.
2004
April 2004 Predictive ADME/Tox congress, High throughput screening for in vitro toxicity testing.
Berlin, Germany.
May 2004 Devgen, High throughput screening for in vitro toxicicity testing. Ghent, Belgium.
Nov 2004 Bioanale, Toxicogenomics and pharmaceutical industry. Maastricht, The Netherlands.
2003
Nov 2003 Biodetection systems, High throughput screening for in vitro toxicity testing.
Amsterdam, The Netherlands.
1999
Febr 1999 Schoonen W.G.E.J., Vermeulen, G.J., Deckers, G.H., Verbost, P.M. and Kloosterboer,
H.J. (1999): Antiprogestins: mechanism of action and in vitro and in vivo selection.
Doorwerth (lecture), Febr . The Netherlands. NVE, Dutch society for endocrinology.
Antiprogestins: mechanism of action and in vitro / in vivo selection.
May 1999 Packard users meeting, Development of in vitro bioassays for high throughput
screening of steroid receptors. London, United Kingdom.
Sept 1999 Schoonen W.G.E.J., Vermeulen, G.J., Deckers, G.H., Verbost, P.M. and Kloosterboer,
H.J. (1999): Antiprogestins: mechanism of action and in vitro and in vivo selection.
Sixth International Congress on Hormones and Cancer. Abstract Page 6. Jerusalem,
Sept 5-9, Israel.
1998
April 1998 Schoonen W.G.E.J. Development of an in vitro assay for progestagenic activity based
on stably transfected CHO cells. Son-discussie groep Farmacochemie, Lunteren, The
Netherlands.
May 1998 Packard users meeting, Development of in vitro bioassays for high throughput
screening of steroid receptors. London, United Kingdom.